Psychedelic Medicine Review at NYU Langone Health 2026

The 2026 Psychedelic Medicine Review, scheduled for April 11, 2026, at NYU Langone Health in New York, explores one of the most rapidly changing areas in modern medicine. This full-day event brings together clinicians and researchers to discuss the remarkable developments in psychedelic treatments that have emerged over the past decade. With compounds like psilocybin, ketamine, and MDMA showing promising results in randomized clinical trials, the field has reached a critical point where scientific progress must be balanced with practical questions about real-world use.

The day provides an overview of current psychedelic research, covering basic science investigations, clinical trials of psychedelic-assisted psychotherapy, and observational studies. Attendees will learn about the latest findings on treatments for mood and anxiety disorders, substance use disorders, and PTSD, while examining the FDA's breakthrough therapy designations for MDMA, psilocybin, and other psychedelic compounds. The program addresses important questions about study methods, effectiveness, safety, and the essential role of therapy that accompanies these treatments.

Beyond the science itself, the conference addresses the complex challenge of bringing research findings into everyday clinical practice. As psychedelic treatments move closer to regulatory approval, healthcare systems face the difficult task of making these interventions widely available while maintaining safety and effectiveness. The event explores health policy considerations, cost concerns, and strategies for ensuring equal access to these potentially transformative treatments. This approach across multiple disciplines reflects the collaborative work necessary for responsible growth in the field, making the course valuable for both clinical practitioners seeking to understand emerging treatments and researchers working to expand our knowledge.